The Food and Drug Administration is requesting that Eli Lilly gather additional safety data on its newly approved weight-loss medication Foundayo, according to the drug's approval letter published Tuesday.

The FDA is specifically asking the pharmaceutical company to monitor for potential liver and heart problems associated with the drug. The request comes as part of the approval process for the weight-loss pill.

Foundayo represents the latest entry in the growing market for weight-loss medications, following the success of other treatments in this therapeutic area. The drug received FDA approval despite the agency's request for additional safety monitoring.

Post-market safety studies are common requirements for newly approved medications, allowing regulators to monitor for adverse effects that may not have been detected during clinical trials. The FDA often requires pharmaceutical companies to conduct additional studies to better understand a drug's safety profile once it reaches a broader patient population.

Eli Lilly will need to submit the requested safety data to the FDA as part of ongoing regulatory oversight of the medication. The timeline and specific parameters for this additional data collection were outlined in the approval letter.